Wellington Management Group
MPLT

Wellington Management Group’s MapLight Therapeutics MPLT Stock Holding History

Wellington Management Group’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86M Buy
51,917
+5,709
+12% +$164K ﹤0.01% 1648
2026
Q1 		$939K Buy
+46,208
New +$827K ﹤0.01% 1687

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group's MPLT Position: Q2 2026 in Review

Wellington Management Group increased its MapLight Therapeutics (MPLT) stake by 12% in Q2 2026, buying an estimated $164K and bringing the position to 51,917 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #1648.

Wellington Management Group first reported a position in MPLT in Q1 2026 and has held it in 2 quarters since. 106 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Wellington Management Group held 51,917 shares of MapLight Therapeutics worth $1.86M as of Q2 2026.
  • Wellington Management Group bought 5,709 MapLight Therapeutics shares in Q2 2026, an estimated $164K.
  • MapLight Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1648 holding.
  • Wellington Management Group first reported a position in MapLight Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 106 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.